HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Signup
Browse Studies

City:   Bennington
State:   Vermont
Zip Code:   05201
Conditions:   Alzheimer's Disease
Purpose:   This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
Study Summary:  
Criteria:   Inclusion Criteria: - Diagnosis of probable AD according to the NINCDS-ADRDA criteria - MMSE score of 18-26 points at screening - GDS-15 score of < 6 - Completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders) - If receiving concurrent AD treatment, patient must be on the medication for at least 3 months at a stable dose for at least 2 months prior to randomization. Exclusion Criteria: - Severe or unstable medical condition that, in the opinion of the investigator or Sponsor, would interfere with the patient's ability to complete the study assessments or would require the equivalent of institutional or hospital care - History or presence of clinically evident vascular disease potentially affecting the brain - History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma - Hospitalization within 4 weeks prior to screening - Previous treatment with MABT5102A or any other therapeutic that targets Abeta - Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed
NCT ID:   NCT01343966
Primary Contact:   Study Director
Robert Paul, M.D., Ph.D.
Genentech

Trial Information Support Line
Phone: 1-888-662-6728 (USA Only)
Backup Contact:   N/A
Location Contact:   Bennington, Vermont 05201
United States



There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   May 19, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


  • NEARBY STUDIES

Within 25 Miles

Within 50 Miles

Gout - Glens Falls NY

Within 100 Miles

Crohn's Disease - Poughkeepsie NY

Crohn's Disease - Worcester MA

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Waterbury CT

Arthritis - Bristol CT

Irritable Bowel Syndrome (with diarrhea) - Poughkeepsie NY

Gout - Worcester MA

Low Back Pain and Constipation - Waterbury CT

COPD (Emphysema and Chronic Bronchitis) - Waterbury CT

COPD (Emphysema and Chronic Bronchitis) - Lebanon NH

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.